Therapeutic Innovation in Pediatric Neuroblastoma: Age and Stage-Specific Strategies from Prenatal to Early Childhood-A Review Article
Iranian Journal of Child Neurology,
Vol. 19 No. 3 (2025),
25 June 2025
,
Page 9-29
https://doi.org/10.22037/ijcn.v19i3.48040
Abstract
Neuroblastoma is one of the most common pediatric cancers, predominantly affecting young children. Despite progress in initial treatments, high-risk cases remain challenging due to frequent relapse or resistance, with long-term survival for relapsed or refractory neuroblastoma below 20%. This highlights an urgent need for novel therapies. Emerging approaches such as GD2-targeted immunotherapy with monoclonal antibodies like dinutuximab, CAR-T cell therapy, 131I-MIBG and Lutetium-177-Dotatate radionuclide treatments, metronomic chemotherapy, oncolytic virotherapy, and tailored chemotherapy are showing promise, with autologous stem cell transplantation (ASCT) becoming integral to multimodal regimens. However, challenges persist, including treatment-related toxicity, tumor resistance, and the logistical limitations of personalized medicine. The future of neuroblastoma treatment lies in exploiting genomic profiling, biomarkers, and combinatorial strategies like immunotherapy paired with radionuclide therapy. Rigorous clinical trials will be key to refining these innovations and establishing protocols for widespread use. In summary, advancements in therapy offer hope, yet achieving durable remissions and improved survival still demands intensive research innovation to address current gaps and resistance mechanisms in this complex pediatric malignancy.
- Neuroblastoma
- Refractory
- Recurrent
- Prenatal
- Immunotherapy
- Dinutuximab
- MIBG therapy
- CAR-T cell
- Luthetium 177- Dotatate
- Metronomic therapy
- Oncolytic virus therapy
How to Cite
References
Smith V, Foster J. High-risk neuroblastoma treatment review. Children. 2018;5(9):114.
Whittle SB, Smith V, Doherty E, Zhao S, McCarty S, Zage PE. Overview and recent advances in the treatment of neuroblastoma. Expert review of anticancer therapy. 2017;17(4):369-86.
DuBois SG, Macy ME, Henderson TO, editors. High-risk and relapsed neuroblastoma: toward more cures and better outcomes. American Society of Clinical Oncology Educational Book American Society of Clinical Oncology Annual Meeting; 2022.
Zage PE, Louis CU, Cohn SLJPb, cancer. New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. Pediatric blood
cancer
;58(7):1099-105.
Navarro S, Amann G, Beiske K, Cullinane CJ, d'Amore ES, Gambini C, et al. Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol. Journal of clinical oncology. 2006;24(4):695-9.
Shimada H, Ambros IM, Dehner LP, Hata Ji, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer: Interdisciplinary International Journal of the American Cancer Society. 1999;86(2):349-63.
Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG task force report. Journal of clinical oncology. 2009;27(2):289-97.
Monclair T, Brodeur GM, Ambros PF, Brisse HJ, Cecchetto G, Holmes K, et al. The international neuroblastoma risk group (INRG) staging system: an INRG task force report. Journal of clinical oncology. 2009;27(2):298-303.
Irwin MS, Naranjo A, Zhang FF, Cohn SL, London WB, Gastier-Foster JM, et al. Revised neuroblastoma risk classification system: a report from the Children's Oncology Group. Journal of Clinical Oncology. 2021;39(29):3229-41.
Schleiermacher G, Mosseri V, London W, Maris J, Brodeur G, Attiyeh E, et al. Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. British journal of cancer. 2012;107(8):1418-22.
Parikh NS, Howard SC, Chantada G, Israels T, Khattab M, Alcasabas P, et al. SIOP‐PODC adapted risk stratification and treatment guidelines: recommendations for neuroblastoma in low‐and middle‐income settings. Pediatric Blood & Cancer. 2015;62(8):1305-16.
Brodeur GM. Spontaneous regression of neuroblastoma. Cell and tissue research. 2018;372:277-86.
Lavarino C, Cheung N-KV, Garcia I, Domenech G, de Torres C, Alaminos M, et al. Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC cancer. 2009;9:1-11.
Twist CJ, Schmidt ML, Naranjo A, London WB, Tenney SC, Marachelian A, et al. Maintaining outstanding outcomes using response-and biology-based therapy for intermediate-risk neuroblastoma: a report from the Children’s Oncology Group study ANBL0531. Journal of Clinical Oncology. 2019;37(34):3243-55.
Nuchtern JG, London WB, Barnewolt CE, Naranjo A, McGrady PW, Geiger JD, et al. A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study. Annals of surgery. 2012;256(4):573-80.
De Bernardi B, Mosseri V, Rubie H, Castel V, Foot A, Ladenstein R, et al. Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group. British journal of cancer. 2008;99(7):1027-33.
Baker DL, Schmidt ML, Cohn SL, Maris JM, London WB, Buxton A, et al. Outcome after reduced chemotherapy for intermediate-risk neuroblastoma. New England Journal of Medicine. 2010;363(14):1313-23.
Krystal J, Foster JH. Treatment of high-risk neuroblastoma. Children. 2023;10(8):1302.
Peinemann F, Van Dalen E, Berthold F. Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients–Cochrane Review. Klinische Pädiatrie. 2016;228(03):130-4.
Amoroso L, Erminio G, Makin G, Pearson AD, Brock P, Valteau-Couanet D, et al. Topotecan-vincristine-doxorubicin in stage 4 high-risk neuroblastoma patients failing to achieve a complete metastatic response to rapid COJEC: A SIOPEN study. Cancer research and treatment: official journal of Korean Cancer Association. 2018;50(1):148-55.
Fischer J, Pohl A, Volland R, Hero B, Dübbers M, Cernaianu G, et al. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months. BMC cancer. 2017;17:1-8.
Castel V, Tovar J, Costa E, Cuadros J, Ruiz A, Rollan V, et al. The role of surgery in stage IV neuroblastoma. Journal of pediatric surgery. 2002;37(11):1574-8.
Mazloom A, Louis CU, Nuchtern J, Kim E, Russell H, Allen-Rhoades W, et al. Radiation therapy to the primary and postinduction chemotherapy MIBG-avid sites in high-risk neuroblastoma. International Journal of Radiation Oncology* Biology* Physics. 2014;90(4):858-62.
Oshiro Y, Mizumoto M, Okumura T, Sugahara S, Fukushima T, Ishikawa H, et al. Clinical results of proton beam therapy for advanced neuroblastoma. Radiation oncology. 2013;8:1-8.
Kushner BH, Ostrovnaya I, Cheung IY, Kuk D, Modak S, Kramer K, et al. Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2015;7(4):4155.
Casey DL, Kushner BH, Cheung N-KV, Modak S, LaQuaglia MP, Wolden SL. Local control with 21-Gy radiation therapy for high-risk neuroblastoma. International Journal of Radiation Oncology* Biology* Physics. 2016;96(2):393-400.
Ng SW, Chan Y, Ng XY, Dua K, Chellappan DK. Neuroblastoma: Current advancements and future therapeutics. Advanced Drug Delivery Systems in the Management of Cancer: Elsevier; 2021. p. 281-97.
Sait S, Modak S. Anti-GD2 immunotherapy for neuroblastoma. Expert review of anticancer therapy. 2017;17(10):889-904.
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, et al. Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. Clinical Cancer Research. 2021;27(8):2179-89.
Ploessl C, Pan A, Maples KT, Lowe DK. Dinutuximab: an anti-GD2 monoclonal antibody for high-risk neuroblastoma. Annals of pharmacotherapy. 2016;50(5):416-22.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, et al. Interleukin 2 with anti-GD2 antibody ch14. 18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial. The Lancet Oncology. 2018;19(12):1617-29.
Achbergerová M, Hederová S, Hrašková A, Kolenová A. Dinutuximab beta in the treatment of high-risk neuroblastoma: A follow-up of a case series in Bratislava. Medicine. 2022;101(4):e28716.
Mora J, Castañeda A, Gorostegui M, Santa‐María V, Garraus M, Muñoz JP, et al. Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission. Pediatric Blood & Cancer. 2021;68(10):e29121.
Morgenstern D, Barone G, Moreno L, Anderson J, Brock P, Elliott M, et al. Options for the treatment of patients with relapsed/progressive high-risk neuroblastoma. Leicester, UK: Children’s Cancer and Leukaemia Group. 2015.
London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, et al. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study. Journal of clinical oncology. 2010;28(24):3808-15.
Schleiermacher G, Javanmardi N, Bernard V, Leroy Q, Cappo J, Rio Frio T, et al. Emergence of new ALK mutations at relapse of neuroblastoma. Journal of Clinical Oncology. 2014;32(25):2727-34.
Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, et al. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer cell. 2014;26(5):682-94.
Herd F, Basta NO, McNally RJ, Tweddle DA. A systematic review of re-induction chemotherapy for children with relapsed high-risk neuroblastoma. European Journal of Cancer. 2019;111:50-8.
Gains JE, Bomanji JB, Fersht NL, Sullivan T, D'Souza D, Sullivan KP, et al. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma. Journal of Nuclear Medicine. 2011;52(7):1041-7.
Yu AL, Gilman AL, Ozkaynak MF, Naranjo A, Diccianni MB, Gan J, et al. Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032. 2021;27(8):2179-89.
Kayano D, Wakabayashi H, Nakajima K, Kuroda R, Watanabe S, Inaki A, et al. High-dose 131 I-metaiodobenzylguanidine therapy in patients with high-risk neuroblastoma in Japan. Annals of nuclear medicine. 2020;34:397-406.
Mastrangelo S, Rufini V, Ruggiero A, Di Giannatale A, Riccardi R. Treatment of advanced neuroblastoma in children over 1 year of age: The critical role of 131I‐metaiodobenzylguanidine combined with chemotherapy in a rapid induction regimen. Pediatric blood & cancer. 2011;56(7):1032-40.
Berthold F, Hömberg M, Proleskovskaya I, Mazanek P, Belogurova M, Ernst A, et al. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma. Pediatric hematology and oncology. 2017;34(5):308-19.
Ramirez M, Garcia-Castro J, Alemany R. Oncolytic virotherapy for neuroblastoma. Discovery Medicine. 2010;10(54):387-93.
Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M, et al. Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta oncologica. 2010;49(1):120-2.
Olgun N, Cecen E, Ince D, Kizmazoglu D, Baysal B, Onal A, et al. Dinutuximab beta plus conventional chemotherapy for relapsed/refractory high-risk neuroblastoma: A single-center experience. Frontiers in Oncology. 2022;12:1041443.
Gray J, Moreno L, Weston R, Barone G, Rubio A, Makin G, et al. BEACON-Immuno: Results of the dinutuximab beta (dB) randomization of the BEACON-Neuroblastoma phase 2 trial—A European Innovative Therapies for Children with Cancer (ITCC–International Society of Paediatric Oncology Europe Neuroblastoma Group (SIOPEN) trial. American Society of Clinical Oncology; 2022.
Castañeda A, Gorostegui M, Miralles S, Chamizo A, Patiño S, Flores M, et al. How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain. ESMO open. 2022;7(2):100462.
Krytska K, Ryles HT, Sano R, Raman P, Infarinato NR, Hansel TD, et al. Crizotinib synergizes with chemotherapy in preclinical models of neuroblastoma. Clinical Cancer Research. 2016;22(4):948-60.
Kushner BH, Cheung IY, Modak S, Kramer K, Ragupathi G, Cheung N-KV. Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clinical cancer research. 2014;20(5):1375-82.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. New England Journal of Medicine. 2023;388(14):1284-95.
Feng J, Cheng FW, Leung AW, Lee V, Yeung EW, Lam HC, et al. Upfront consolidation treatment with 131I-mIbG followed by myeloablative chemotherapy and hematopoietic stem cell transplantation in high-risk neuroblastoma. Pediatric Investigation. 2020;4(03):168-77.
Mastrangelo S, Attinà G, Zagaria L, Romano A, Ruggiero A. Induction regimen in high-risk neuroblastoma: a pilot study of highly effective continuous exposure of tumor cells to radio-chemotherapy sequence for 1 month. the critical role of iodine-131-metaiodobenzylguanidine. Cancers. 2022;14(20):5170.
Kraal KC, Tytgat GA, van Eck‐Smit BL, Kam B, Caron HN, van Noesel M. Upfront treatment of high‐risk neuroblastoma with a combination of 131I‐MIBG and topotecan. Pediatric blood & cancer. 2015;62(11):1886-91.
Weiss BD, Yanik G, Naranjo A, Zhang FF, Fitzgerald W, Shulkin BL, et al. A safety and feasibility trial of 131I‐MIBG in newly diagnosed high‐risk neuroblastoma: A Children's Oncology Group study. Pediatric blood & cancer. 2021;68(10):e29117.
Kraal K, Bleeker G, van Eck-Smit B, van Eijkelenburg N, Berthold F, Van Noesel M, et al. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients. European Journal of Cancer. 2017;76:188-96.
Moreno L, Moroz V, Owens C, Valteau-Couanet D, Gambart M, Castel V, et al. Bevacizumab for children with relapsed & refractory high-risk neuroblastoma (RR-HRNB): Results of the BEACON-neuroblastoma randomized phase II trial-A European ITCC-SIOPEN trial. Annals of Oncology. 2019;30:v901.
Kramer K, Kushner BH, Modak S, Pandit-Taskar N, Smith-Jones P, Zanzonico P, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. Journal of neuro-oncology. 2010;97:409-18.
Desai AV, Elmuti L, Cahaney C, De Guzman RM, Streby KA, Cohn SL. Multimodality treatment for recurrent neuroblastoma in the central nervous system. Pediatric Blood & Cancer. 2023;70(4):e30227.
Sundquist F, Georgantzi K, Jarvis KB, Brok J, Koskenvuo M, Rascon J, et al. A Phase II trial of a personalized, dose-intense administration schedule of 177Lutetium-DOTATATE in children with primary refractory or relapsed high-risk neuroblastoma–LuDO-N. Frontiers in pediatrics. 2022;10:836230.
Fathpour G, Jafari E, Hashemi A, Dadgar H, Shahriari M, Zareifar S, et al. Feasibility and therapeutic potential of combined peptide receptor radionuclide therapy with intensive chemotherapy for pediatric patients with relapsed or refractory metastatic neuroblastoma. Clinical Nuclear Medicine. 2021;46(7):540-8.
Alavi S. Paraneoplastic neurologic syndromes in children: a review article. Iranian Journal of Child Neurology. 2013;7(3):6.
Alavi S, Valeshabad K, Moradveisi B, Aminasnafi A, Arzanian M. Clinical responses to rituximab in a case of neuroblastoma with refractory opsoclonus myoclonus ataxia syndrome. Case Reports in Oncological Medicine. 2012;2012:164082-.
Klement G. Chronically sustained regressions of human tumor xenografts in the absence of overt toxicity by continuous low-dose vinblastine and anti-VEGF receptor-2 antibody therapy. J Clin Invest. 2000;105:R15-24.
Marimpietri D, Nico B, Vacca A, Mangieri D, Catarsi P, Ponzoni M, et al. Synergistic inhibition of human neuroblastoma-related angiogenesis by vinblastine and rapamycin. Oncogene. 2005;24(45):6785-95.
Russell HV, Groshen SG, Ara T, DeClerck YA, Hawkins R, Jackson HA, et al. A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. Pediatric blood & cancer. 2011;57(2):275-82.
André N, Abed S, Orbach D, Alla CA, Padovani L, Pasquier E, et al. Pilot study of a pediatric metronomic 4-drug regimen. Oncotarget. 2011;2(12):960.
Sun X, Zhen Z, Guo Y, Gao Y, Wang J, Zhang Y, et al. Oral metronomic maintenance therapy can improve survival in high-risk neuroblastoma patients not treated with ASCT or anti-GD2 antibodies. Cancers. 2021;13(14):3494.
Carcamo B, Francia G. Cyclic metronomic chemotherapy for pediatric tumors: Six case reports and a review of the literature. Journal of Clinical Medicine. 2022;11(10):2849.
- Abstract Viewed: 332 times